A Phase 1, First-in-human, 2-part, Randomized, Double-blind, Placebo-controlled, Parallel-group, Single Ascending Dose and Multiple Ascending Dose (SAD/MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ENN0403 in Healthy Adult Subjects
Latest Information Update: 20 Sep 2024
At a glance
- Drugs ENN-0403 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors EnnovaBio
- 24 Aug 2022 New trial record